A new order in BTK inhibition
Imbruvica faces challenges on multiple fronts.
Imbruvica faces challenges on multiple fronts.
MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.
The group highlights safety and manufacturability, as well as efficacy, but investors apparently have doubts.
Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.
Competitors struggle, while MorphoSys investors see a path forward for pelabresib after all.
Dizal got a lucky break with golidocitinib, and now mid-stage data back the project’s activity in T-cell lymphoma.